- Clinical Trials
- February 2024
- 80 Pages
Global
From €1904EUR$2,000USD£1,628GBP
- Report
- January 2024
- 285 Pages
Global
From €9045EUR$9,500USD£7,731GBP
- Report
- March 2019
- 110 Pages
Global
From €3094EUR$3,250USD£2,645GBP
- Report
- June 2018
- 14 Pages
Global
From €9521EUR$10,000USD£8,138GBP
- Clinical Trials
- January 2020
- 500 Pages
Global
From €2285EUR$2,400USD£1,953GBP
- Report
- September 2019
Global
From €5113EUR$5,370USD£4,370GBP
Rytary is a brand of central nervous system (CNS) drugs used to treat Parkinson's disease and other movement disorders. It is a combination of two drugs, carbidopa and levodopa, which work together to increase the amount of dopamine in the brain. Rytary is available in both immediate-release and extended-release formulations, allowing for more flexibility in dosing. The extended-release formulation is designed to provide a more consistent level of dopamine throughout the day, reducing the need for frequent dosing.
Rytary is a popular choice for treating Parkinson's disease, as it is effective in controlling symptoms and has fewer side effects than other CNS drugs. It is also used to treat restless leg syndrome, a condition characterized by an urge to move the legs.
Rytary is manufactured by Impax Laboratories, Inc. and marketed by Acorda Therapeutics, Inc. Other companies in the market include Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more